Literature DB >> 32474577

Diligent Medical Activities of a Publicly Designated Medical Institution for Infectious Diseases Pave the Way for Overcoming COVID-19: A Positive Message to People Working at the Cutting Edge.

Tatsuya Nagano1, Jun Arii2, Mitsuhiro Nishimura2, Naofumi Yoshida3, Keiji Iida4, Yoshihiro Nishimura1, Yasuko Mori2.   

Abstract

Entities:  

Mesh:

Year:  2021        PMID: 32474577      PMCID: PMC7314194          DOI: 10.1093/cid/ciaa694

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
To the Editor—Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has spread worldwide [1]. The possibility of virus transmission from patients with COVID-19 to medical staff is of primary concern. Recently, Htun et al [2] performed hospital-wide fever and sickness surveillance for 1524 medical staff working in COVID-19 areas and showed that all medical staff who suffered from fever were negative for SARS-CoV-2 by polymerase chain reaction (PCR) test. However, screening for COVID-19 in medical staff without fever is also important, since the asymptomatic proportion of COVID-19 cases was estimated to be 17.9% [3]. Therefore, on 1, 7, and 8 May 2020 we collected sera from 509 healthy medical staff members working to treat patients with COVID-19 at the Hyogo Prefectural Kakogawa Medical Center, which has 353 beds and is 1 of 55 publicly designated medical institutions for infectious diseases—including Ebola, smallpox, plague, tuberculosis, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS)—in Japan. Immunoglobulin G (IgG) antibodies for SARS-CoV-2 in each serum sample were analyzed by immunochromatographic test (2019-nCoV Ab Test; INNOVITA, Hebei, China), which includes colloidal gold coated with spike and nucleocapsid protein of SARS-CoV-2 as a tracer. The mean number of hospitalized patients with COVID-19 was 20 (95% confidence interval, 18–22). The 509 medical staff members consisted of 88 men and 421 women with a median age of 39 (range, 18–66) years. They were 77 doctors, 310 nurses, 1 pharmacist, 20 radiology technicians, 19 laboratory medical technologists, and 82 medical assistants. A total of 115, 18, and 72 worked in the intensive care unit, the ambulatory unit for patients with fever, and the ward for patients with COVID-19, respectively. The mean time from contact with patients with COVID-19 to sera collection was 24 days (95% confidence interval, 23–25 days). None of the medical staff in the hospital had IgG antibodies for SARS-CoV-2, whereas sera from patients with COVID-19 in the hospital, which were used as a positive control, showed a 100% (10/10) positive rate for IgG, suggesting the high specificity of the immunochromatographic test used here. In addition, the time-series behavior of IgG in sera from these patients was examined and is shown in Figure 1. Taken together, these results indicate that transmission from patients to medical staff did not occur in these medical staff members, and the standard preventive measures against infectious diseases can prevent SARS-CoV-2 exposure in medical staff.
Figure 1.

The time-series behavior of IgG in sera from patients with COVID-19 by immunochromatographic test (INNOVITA, Hebei, China). “+” or “−“ indicates positive or negative IgG for SARS-CoV-2 at each time point. The symptom onset date was reported from each patient. Abbreviations: COVID-19, coronavirus disease 2019; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

The time-series behavior of IgG in sera from patients with COVID-19 by immunochromatographic test (INNOVITA, Hebei, China). “+” or “−“ indicates positive or negative IgG for SARS-CoV-2 at each time point. The symptom onset date was reported from each patient. Abbreviations: COVID-19, coronavirus disease 2019; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Despite the hard work of the brave medical workers around the world, many patients continue to die of COVID-19 [4]. Unfortunately, not just a few medical staff members have also died from nosocomial infections of SARS-CoV-2. The medical staff at the Kakogawa Medical Center have been in contact with patients with COVID-19 for up to 53 days, but so far there have been no incidents suspicious for nosocomial infection. Our surprising results suggest that standard preventive measures, if strictly followed, can prevent SARS-CoV-2 exposure in medical practitioners. Although all medical workers naturally fear SARS-CoV-2 exposure, we believe the current results could help alleviate their anxiety, and could provide courage and inspiration for their fight against COVID-19.
  3 in total

1.  Responding to the COVID-19 Outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems.

Authors:  Htet Lin Htun; Dwee Wee Lim; Win Mar Kyaw; Wan-Ning Janis Loh; Lay Tin Lee; Brenda Ang; Angela Chow
Journal:  Clin Infect Dis       Date:  2020-11-05       Impact factor: 9.079

Review 2.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

Authors:  James M Sanders; Marguerite L Monogue; Tomasz Z Jodlowski; James B Cutrell
Journal:  JAMA       Date:  2020-05-12       Impact factor: 56.272

3.  Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020.

Authors:  Kenji Mizumoto; Katsushi Kagaya; Alexander Zarebski; Gerardo Chowell
Journal:  Euro Surveill       Date:  2020-03
  3 in total
  5 in total

1.  Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia.

Authors:  Ni Luh Ayu Megasari; Takako Utsumi; Laura Navika Yamani; Emily Gunawan; Koichi Furukawa; Mitsuhiro Nishimura; Maria Inge Lusida; Yasuko Mori
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

2.  Massive surge of mRNA expression of clonal B-cell receptor in patients with COVID-19.

Authors:  Yohei Funakoshi; Goh Ohji; Kimikazu Yakushijin; Kei Ebisawa; Yu Arakawa; Jun Saegusa; Hisayuki Matsumoto; Takamitsu Imanishi; Eriko Fukuda; Takaji Matsutani; Yasuko Mori; Kentaro Iwata; Hironobu Minami
Journal:  Heliyon       Date:  2021-08-10

3.  Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.

Authors:  Koichi Furukawa; Lidya Handayani Tjan; Yukiya Kurahashi; Silvia Sutandhio; Mitsuhiro Nishimura; Jun Arii; Yasuko Mori
Journal:  JAMA Netw Open       Date:  2022-05-02

4.  Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan.

Authors:  Koichi Furukawa; Jun Arii; Mitsuhiro Nishimura; Lidya Handayani Tjan; Anna Lystia Poetranto; Zhenxiao Ren; Salma Aktar; Jing Rin Huang; Silvia Sutandhio; Yukiya Kurahashi; Arisa Nishino; Shiho Shigekuni; Yuichiro Takeda; Kenichi Uto; Keiji Matsui; Itsuko Sato; Yoshiaki Inui; Kazuo Endo; Yoshiyuki Kosaka; Toshiaki Oota; Jun Saegusa; Yasuko Mori
Journal:  JMA J       Date:  2021-01-14

5.  Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan.

Authors:  Koichi Furukawa; Lidya Handayani Tjan; Silvia Sutandhio; Yukiya Kurahashi; Sachiyo Iwata; Yoshiki Tohma; Shigeru Sano; Sachiko Nakamura; Mitsuhiro Nishimura; Jun Arii; Tatsunori Kiriu; Masatsugu Yamamoto; Tatsuya Nagano; Yoshihiro Nishimura; Yasuko Mori
Journal:  Open Forum Infect Dis       Date:  2021-08-18       Impact factor: 3.835

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.